UroGen Pharma Ltd. (URGN)
NASDAQ: URGN
· Real-Time Price · USD
13.34
0.23 (1.75%)
At close: Jun 27, 2025, 11:21 AM
1.75% (1D)
| Bid | 13.3 |
| Market Cap | 615.07M |
| Revenue (ttm) | 91.87M |
| Net Income (ttm) | -138.43M |
| EPS (ttm) | -3.01 |
| PE Ratio (ttm) | -4.43 |
| Forward PE | -19.03 |
| Analyst | Buy |
| Ask | 13.38 |
| Volume | 487,453 |
| Avg. Volume (20D) | 2,830,116 |
| Open | 13.23 |
| Previous Close | 13.11 |
| Day's Range | 13.01 - 13.49 |
| 52-Week Range | 3.42 - 18.15 |
| Beta | 0.40 |
About URGN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol URGN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for URGN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
UroGen Pharma Ltd. is scheduled to release its earnings on Aug 12, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
+8.57%
UroGen Pharma shares are trading higher after Gugg...
Unlock content with
Pro Subscription
2 weeks ago
+51.78%
UroGen Pharma shares are trading higher after the FDA approved ZUSDURI for intravesical solution a the first and only medication for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.
